Servier Egypt launches Tibsovo as first targeted therapy for IDH1-mutated cancers
Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The new treatment offers a median overall survival of 29.3 months for eligible AML patients
Servier Egypt celebrates jubilee with new production line, cancer programme
Servier Egypt, part of the global Servier Group, has commemorated its 70th anniversary with the opening of a new production line and the launch of the “Access Cancer Treatment (ACT) for Children” initiative. The announcements were made at an